{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:48:31Z","timestamp":1789523311964,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Numerous chronic inflammatory skin diseases are associated with the release of proinflammatory cytokines, which act via the intracellular JAK\u2010STAT pathway. JAK inhibitors represent a promising, targeted therapeutic approach for cutaneous diseases. Impressive effects have been achieved with these agents in recent years. With the approval of the JAK\u2010inhibitors Baricitinib, Upadacitinib and Abrocitinib, new systemic therapeutic agents are now available for moderate to severe atopic dermatitis. Other diseases in which the effectiveness of these small molecules could be shown are psoriasis, chilblain lupus, dermatomyositis, vitiligo and alopecia areata. As dermatologists, we are facing a whole series of new drug approvals. In this minireview we explain the active principles of JAK inhibitors and review study results in selected inflammatory skin diseases. Finally, possible side effects and initial as well as follow\u2010up laboratory examinations for these drugs are discussed.<\/jats:p>","DOI":"10.1111\/ddg.14668","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T09:04:11Z","timestamp":1640682251000},"page":"19-24","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["JAK\u2010inhibitors in dermatology \u2013 small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects"],"prefix":"10.1111","volume":"20","author":[{"given":"Benjamin","family":"Klein","sequence":"first","affiliation":[{"name":"Department of Dermatology Allergology and Venereology Leipzig University Medical Center  Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Treudler","sequence":"additional","affiliation":[{"name":"Department of Dermatology Allergology and Venereology Leipzig University Medical Center  Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Dermatology Allergology and Venereology Leipzig University Medical Center  Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.022"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3260"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.025"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00589-4"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.042"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.015"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"e_1_2_12_15_1","unstructured":"Bristol Myers Squibb presents positive data from two pivotal phase 3 psoriasis studies demonstrating superiority of deucravacitinib compared to placebo and otezla\u00ae (apremilast). Available from:https:\/\/news.bms.com\/news\/details\/2021\/Bristol\u2010Myers\u2010Squibb\u2010Presents\u2010Positive\u2010Data\u2010from\u2010Two\u2010Pivotal\u2010Phase\u20103\u2010Psoriasis\u2010Studies\u2010Demonstrating\u2010Superiority\u2010of\u2010Deucravacitinib\u2010Compared\u2010to\u2010Placebo\u2010and\u2010Otezla\u2010apremilast\/default.aspx[Last accessed July 17 2021]."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00347-w"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007811"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15489"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.043"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98814"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.02.015"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.5077"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900045"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14276_g"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab116"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18469"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.012"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.098"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.12.019"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41580"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.14668","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.14668","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.14668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T02:19:12Z","timestamp":1693102752000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.14668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1111\/ddg.14668"],"URL":"https:\/\/doi.org\/10.1111\/ddg.14668","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,28]]},"assertion":[{"value":"2021-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}